Oldhamianoside II Inhibits Prostate Cancer Progression Via Regulation of EMT and the Wnt/β-catenin Signaling Pathway

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 May 29

PMID 29805669

Citations 2

Authors

Kaizhi Li

Xuemei Zhan

Jingyong Sun

Tianfeng Wang

Hongyan Dong

Fanbo Jing

Dongmei Li

Yu Cao

Yali Liu

Lin Wang

Shengnan Li

Affiliations

Soon will be listed here.

Abstract

Oldhamianoside II is a novel triterpenoidsaponin that can be isolated from the roots of . and experiments have revealed that it inhibits tumor growth and metastasis in various types of tumor; however, the exact mechanism remains to be fully elucidated. In the present study, oldhamianoside II treatment in prostate cancer cells exerted substantial anticancer activity, including decreased cell proliferation and invasion. Mechanistically, oldhamianoside II was found to reverse the epithelial-mesenchymal transition (EMT), as demonstrated by its induction of E-cadherin and suppression of vimentin and N-cadherin at the mRNA and protein levels. Furthermore, oldhamianoside II treatment upregulated Wnt antagonist expression and promoted the proteasome-mediated degradation of β-catenin to inhibit the activity of β-catenin signaling. In summary, the present study revealed that oldhamianoside II exerts its antitumor effects via the regulation of EMT and β-catenin function, and further supports its potential for use in clinical treatment.

Citing Articles

Wnt/β-catenin-driven EMT regulation in human cancers.

Xue W, Yang L, Chen C, Ashrafizadeh M, Tian Y, Sun R Cell Mol Life Sci. 2024; 81(1):79.

PMID: 38334836 PMC: 10857981. DOI: 10.1007/s00018-023-05099-7.

Natural Compounds in Sex Hormone-Dependent Cancers: The Role of Triterpenes as Therapeutic Agents.

Soica C, Voicu M, Ghiulai R, Dehelean C, Racoviceanu R, Trandafirescu C Front Endocrinol (Lausanne). 2021; 11:612396.

PMID: 33552000 PMC: 7859451. DOI: 10.3389/fendo.2020.612396.

References

Yokoyama N, Shao S, Hoang B, Mercola D, Zi X . Wnt signaling in castration-resistant prostate cancer: implications for therapy. Am J Clin Exp Urol. 2014; 2(1):27-44. PMC: 4219296. View

Sundram V, Chauhan S, Ebeling M, Jaggi M . Curcumin attenuates β-catenin signaling in prostate cancer cells through activation of protein kinase D1. PLoS One. 2012; 7(4):e35368. PMC: 3327669. DOI: 10.1371/journal.pone.0035368. View

Fischer J . Deubiquitinating enzymes: their roles in development, differentiation, and disease. Int Rev Cytol. 2003; 229:43-72. DOI: 10.1016/s0074-7696(03)29002-1. View

Giles R, van Es J, Clevers H . Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta. 2003; 1653(1):1-24. DOI: 10.1016/s0304-419x(03)00005-2. View

Gonzalez D, Medici D . Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal. 2014; 7(344):re8. PMC: 4372086. DOI: 10.1126/scisignal.2005189. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Thiery J, Acloque H, Huang R, Nieto M . Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139(5):871-90. DOI: 10.1016/j.cell.2009.11.007. View

Bullions L, Levine A . The role of beta-catenin in cell adhesion, signal transduction, and cancer. Curr Opin Oncol. 1998; 10(1):81-7. DOI: 10.1097/00001622-199801000-00013. View

Wang L, Li Y, Yang X, Yuan H, Li X, Qi M . ERG-SOX4 interaction promotes epithelial-mesenchymal transition in prostate cancer cells. Prostate. 2014; 74(6):647-58. DOI: 10.1002/pros.22783. View

10.

Dai J, Hall C, Escara-Wilke J, Mizokami A, Keller J, Keller E . Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. Cancer Res. 2008; 68(14):5785-94. PMC: 4432935. DOI: 10.1158/0008-5472.CAN-07-6541. View

11.

Kagey M, He X . Rationale for targeting the Wnt signalling modulator Dickkopf-1 for oncology. Br J Pharmacol. 2017; 174(24):4637-4650. PMC: 5727329. DOI: 10.1111/bph.13894. View

12.

Arend R, Londono-Joshi A, Straughn Jr J, Buchsbaum D . The Wnt/β-catenin pathway in ovarian cancer: a review. Gynecol Oncol. 2013; 131(3):772-9. DOI: 10.1016/j.ygyno.2013.09.034. View

13.

Logan C, Nusse R . The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004; 20:781-810. DOI: 10.1146/annurev.cellbio.20.010403.113126. View

14.

Koch A, Waha A, Hartmann W, Hrychyk A, Schuller U, Waha A . Elevated expression of Wnt antagonists is a common event in hepatoblastomas. Clin Cancer Res. 2005; 11(12):4295-304. DOI: 10.1158/1078-0432.CCR-04-1162. View

15.

Wang L, Zheng Y, Xu H, Yan X, Chang X . Investigate pathogenic mechanism of TXNDC5 in rheumatoid arthritis. PLoS One. 2013; 8(1):e53301. PMC: 3541148. DOI: 10.1371/journal.pone.0053301. View

16.

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

17.

MacDonald B, Tamai K, He X . Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009; 17(1):9-26. PMC: 2861485. DOI: 10.1016/j.devcel.2009.06.016. View

18.

Nauseef J, Henry M . Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle?. Nat Rev Urol. 2011; 8(8):428-39. PMC: 6858788. DOI: 10.1038/nrurol.2011.85. View

19.

Heidenreich A, Aus G, Bolla M, Joniau S, Matveev V, Schmid H . EAU guidelines on prostate cancer. Eur Urol. 2007; 53(1):68-80. DOI: 10.1016/j.eururo.2007.09.002. View

20.

Wang L, Yang X, Chang Y, Qi M, Zhou Z, Zhang J . SOX4 is associated with poor prognosis in prostate cancer and promotes epithelial-mesenchymal transition in vitro. Prostate Cancer Prostatic Dis. 2013; 16(4):301-7. DOI: 10.1038/pcan.2013.25. View